Revvity Is Balancing FX Gains, Margin Challenges, & Growth—Which Side Will Win Out?

Revvity Inc.’s Q2 2025 results reflect steady performance amidst challenging market and regulatory conditions. Organic revenue growth of 3% was achieved, aligning with the company’s initial forecasts. Revenue reached $720 million, bolstered by strong performances, particularly in the Life Sciences segment, which saw 4% organic growth. This segment’s growth was significantly driven by the success of the Signals software franchise, achieving approximately 30% growth and setting records for order volumes, thereby indicating a promising future.